Idiosyncratic Drug-induced Liver Injury Caused by Givosiran in a Patient with Acute Intermittent Porphyria

Overview

Journal Mol Genet Metab Rep

Specialty Endocrinology

Date 2022 Dec 29

PMID 36578356

Authors

Christopher D Ma

Denise Faust

Herbert L Bonkovsky

Affiliations

Soon will be listed here.

Abstract

A 39-year-old woman with biochemically and clinically active acute intermittent porphyria (AIP) developed moderately severe liver injury after receiving her second dose of givosiran. Serologic evaluation ruled out hepatitis caused by viral, autoimmune, or other metabolic etiologies. The updated Roussel Uclaf Causality Assessment Method (RUCAM) score was 8 and the Revised Electronic Causality Assessment Method (RECAM) score for givosiran was 9. Results of liver tests returned to normal after givosiran was discontinued, and she has not received any more givosiran.

Citing Articles

Drug Induced Liver Injury: Highlights and Controversies in the 2023 Literature.

Singh H, Kunkle B, Troia A, Suvarnakar A, Waterman A, Khin Y Drug Saf. 2025; .

PMID: 39921708 DOI: 10.1007/s40264-025-01514-z.

Human Leucocyte Antigen Genetics in Idiosyncratic Drug-Induced Liver Injury with Evidence Based on the Roussel Uclaf Causality Assessment Method.

Teschke R, Danan G Medicines (Basel). 2024; 11(4).

PMID: 38667507 PMC: 11052120. DOI: 10.3390/medicines11040009.

References

Poli A, Schmitt C, Moulouel B, Mirmiran A, Talbi N, Riviere S . Givosiran in acute intermittent porphyria: A personalized medicine approach. Mol Genet Metab. 2022; 135(3):206-214. DOI: 10.1016/j.ymgme.2022.01.002. View

Chalasani N, Bonkovsky H, Stine J, Gu J, Barnhart H, Jacobsen E . Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study. J Hepatol. 2021; 76(4):832-840. PMC: 8944173. DOI: 10.1016/j.jhep.2021.12.013. View

Danan G, Teschke R . Roussel Uclaf Causality Assessment Method for Drug-Induced Liver Injury: Present and Future. Front Pharmacol. 2019; 10:853. PMC: 6680600. DOI: 10.3389/fphar.2019.00853. View

Katarey D, Verma S . Drug-induced liver injury. Clin Med (Lond). 2016; 16(Suppl 6):s104-s109. PMC: 6329561. DOI: 10.7861/clinmedicine.16-6-s104. View

Balwani M, Sardh E, Ventura P, Aguilera Peiro P, Rees D, Stolzel U . Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. N Engl J Med. 2020; 382(24):2289-2301. DOI: 10.1056/NEJMoa1913147. View

Honor A, Rudnick S, Bonkovsky H . Givosiran to treat acute porphyria. Drugs Today (Barc). 2021; 57(1):47-59. DOI: 10.1358/dot.2021.57.1.3230207. View

Ventura P, Bonkovsky H, Gouya L, Aguilera-Peiro P, Bissell D, Stein P . Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study. Liver Int. 2021; 42(1):161-172. PMC: 9299194. DOI: 10.1111/liv.15090. View

Hayashi P, Lucena M, Fontana R, Bjornsson E, Aithal G, Barnhart H . A revised electronic version of RUCAM for the diagnosis of DILI. Hepatology. 2022; 76(1):18-31. PMC: 9233102. DOI: 10.1002/hep.32327. View

Danan G, Teschke R . RUCAM in Drug and Herb Induced Liver Injury: The Update. Int J Mol Sci. 2015; 17(1). PMC: 4730261. DOI: 10.3390/ijms17010014. View

10.

Majeed C, Ma C, Xiao T, Rudnick S, Bonkovsky H . Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy. Drug Des Devel Ther. 2022; 16:1827-1845. PMC: 9208469. DOI: 10.2147/DDDT.S281631. View

11.

Zhao L, Wang X, Zhang X, Liu X, Ma N, Zhang Y . Therapeutic strategies for acute intermittent porphyria. Intractable Rare Dis Res. 2020; 9(4):205-216. PMC: 7586882. DOI: 10.5582/irdr.2020.03089. View

12.

Hoofnagle J, Bonkovsky H, Phillips E, Li Y, Ahmad J, Barnhart H . HLA-B*35:01 and Green Tea-Induced Liver Injury. Hepatology. 2020; 73(6):2484-2493. PMC: 8052949. DOI: 10.1002/hep.31538. View

13.

DAco K, Bearden D, Watkins D, Hyland K, Rosenblatt D, Ficicioglu C . Severe 5,10-methylenetetrahydrofolate reductase deficiency and two MTHFR variants in an adolescent with progressive myoclonic epilepsy. Pediatr Neurol. 2014; 51(2):266-70. DOI: 10.1016/j.pediatrneurol.2014.04.005. View

14.

Norman B . Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies. J Med Chem. 2020; 63(20):11397-11419. DOI: 10.1021/acs.jmedchem.0c00524. View

15.

Fontanellas A, Avila M, Arranz E, Enriquez de Salamanca R, Morales-Conejo M . Acute intermittent porphyria, givosiran, and homocysteine. J Inherit Metab Dis. 2021; 44(4):790-791. PMC: 8370099. DOI: 10.1002/jimd.12411. View

16.

Petrides P, Klein M, Schuhmann E, Torkler H, Molitor B, Loehr C . Severe homocysteinemia in two givosiran-treated porphyria patients: is free heme deficiency the culprit?. Ann Hematol. 2021; 100(7):1685-1693. PMC: 8195940. DOI: 10.1007/s00277-021-04547-3. View

17.

Sardh E, Harper P, Balwani M, Stein P, Rees D, Bissell D . Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria. N Engl J Med. 2019; 380(6):549-558. DOI: 10.1056/NEJMoa1807838. View

18.

To-Figueras J, Wijngaard R, Garcia-Villoria J, Aarsand A, Aguilera P, Deulofeu R . Dysregulation of homocysteine homeostasis in acute intermittent porphyria patients receiving heme arginate or givosiran. J Inherit Metab Dis. 2021; 44(4):961-971. DOI: 10.1002/jimd.12391. View